PPARG and hepatitis C virus infection: Despite the promising results, clinical development of PPARγ agonists for hepatitis C was stopped when new and more potent pharmacotherapy, direct-acting antivirals, was approved by the FDA in 2011 for hepatitis C treatment [216].